On the seventh day of Christmas life science gave to me…firms that are a-winning
We’ve created our very own 12 days of Christmas for the life science sector. Via news brands Medical Plastics News, Digital Health Age and European Pharmaceutical Manufacturer we’ll be looking back on 2015 in festive form
On the seventh day of Christmas life science gave to me…
… firms that are a-winning, nicotine a-spraying, the internet of things, an app to help with words, French epi-pens, new robotic gloves and devices for cardiology
2015 saw some exciting company success stories in the pharmaceutical sector.
Big pharma player Pfizer inked its long-rumoured deal to buy botox maker Allergan, in what the BBC described as the ‘biggest pharmaceuticals deal in history’. Pfizer revealed it will have its global operational HQ in New York and its principal executive offices in Ireland.
It’s been a good year for Catalent Pharma Solutions. The company announced a multi-site expansion of its analytical and process development capabilities for biologics.
Catalent’s expansions include a development of bioassay and protein characterisation capabilities at its Kansas City, Missouri facility and integrated analytical capabilities at its Madison, Wisconsin bio-manufacturing facility.
Meanwhile Pelago Bioscience and AstraZeneca entered into a two-year strategic research collaboration and license agreement. During the collaboration Pelago and AstraZeneca will develop assay formats and applications of the CETSA method that are relevant to AstraZeneca’s range of therapeutic areas.
A key player in the sector, Schott celebrated its 80th manufacturing anniversary by investing more in its pharmaceutical plant in Itupeva, Brazil. Then company revealed that it plans to support growing domestic pharmaceutical companies by supplying locally manufactured high-quality packaging
Breakthroughs have been rife over the last twelve months highlighting the expertise in the pharma sector. With the announcement that Sanofi and BioNTech had teamed up for a research collaboration and license agreement , we also learned that five cancer immunotherapies would be created by the union.